ResMed Share Price Rises 0.69%: Up 2.7% in Five Sessions
Technical analysis of ResMed stock on November 16, 2026: price 35.20 AUD, trend uptrend, RSI 60.2, support 33.32, resistance 35.91.

ResMed rose 0.69% to A$35.20 on Monday, November 16, 2026, extending gains over five sessions to 2.71%. The technical picture is constructive, but momentum has softened and trading volume was thin. That makes the advance worth watching, rather than unambiguous.
Why ResMed is in focus today
Selected automatically from 6 ASX (Australia) stocks by a technical-signal score with daily weighted randomisation — not a recommendation.
Trend & Price Action
The share price is above both its 20-day simple moving average (SMA), at A$34.68, and its 50-day average, at A$33.07. The 20-day average is rising 0.50% over five days, while the 20-day average remains above the 50-day average. Together, those readings support the stated uptrend; no new moving-average crossover formed in the latest session.
Price is 73% of the way through its 20-day range, between support at A$33.32 and resistance at A$35.91. It is also below the three-month high of A$37.67, after trading as low as A$30.23 during that period. The position near resistance means further gains would need to clear a nearby hurdle before the broader three-month high comes into view.
As shown in the chart, the price sits above its moving averages and within the Bollinger bands, with resistance close overhead.

Oscillators & Momentum
RSI is neutral at 60.2, and the Stochastic readings are also neutral, with %K at 51.9 and %D at 45.7. These indicators do not show an overbought or oversold extreme. The MACD, however, is weaker: its value of 0.368 is below the 0.417 signal line, leaving a negative histogram of -0.049. That suggests upward price structure has not yet translated into strengthening short-term momentum.
The mix matters: neutral oscillators leave room for movement either way, while the negative MACD cautions that the latest rise lacks full momentum confirmation. As shown in the chart, the RSI and Stochastic are neutral while MACD remains below its signal line.

Volatility, Volume & Levels
The Bollinger bands are at A$33.16 on the lower side and A$36.21 on the upper side, with price at 67% of the band range. Their 8.8% width is normal, not a squeeze or a sharp expansion. The average true range (ATR) is A$0.94, or 2.7% of the share price, indicating moderate daily volatility rather than unusually wide swings.
Volume was 1,003,195 shares, about half the 20-session average of 2,013,804, which marks the latest activity as thin. Rising on-balance volume (OBV), a measure that tracks whether volume tends to accompany gains or losses, offers a counterpoint: participation has been building over time even though this session was quiet.
A move through A$35.91 resistance would clear the stated 20-day ceiling; failure to hold above the A$34.68 20-day average would weaken the near-term trend. The A$33.32 support and A$33.16 lower Bollinger band mark nearby downside reference points, while the three-month high at A$37.67 is a broader chart level.
Technical Verdict: BUY
The technical verdict is BUY, in line with JournalArta Research’s score of +84. The strongest supports are the price above its 50-day average and an uptrend confirmed by rising OBV; the 20-day average is also above the 50-day average. The main caution is the negative MACD histogram, alongside thin latest-session volume. The verdict is invalidated if price falls below A$33.13.
- Ideal entry range: A$34.50–A$35.20
- Exit targets: A$38.30 (Target 1) and A$41.41 (Target 2)
- Stop-loss protection: A$33.13
- Validity: Through December 14, 2026
In plain English, the chart leans upward, but the momentum and trading activity still call for caution.
Summary Data ResMed
| Last price | 35.20 AUD |
| Change 1 day / 5 days / 1 month | 0.69% / 2.71% / 3.32% |
| Trend / MA-cross | uptrend / none |
| SMA20 / SMA50 | 34.68 / 33.07 |
| RSI (14) / Stochastic %K | 60.2 / 51.9 |
| Bollinger %B / ATR | 67% / 0.94 |
| Support / Resistance 20 days | 33.32 / 35.91 |
| Data as of | 16 November 2026 12:10 WIB |
| JournalArta research verdict (score) | Buy (+84) |
| Entry zone | 34.50 – 35.20 |
| Target 1 / 2 | 38.30 / 41.41 |
| Stop loss | 33.13 |
| Reward/risk | 1.5 / 3.0 |
Today's full Buy and Sell list for Australian stocks (ASX) →
Disclaimer: This technical analysis is generated automatically from exchange data and indicators calculated by JournalArta, for information and education only. The verdict and the entry, target and stop-loss levels are not investment advice or a solicitation to buy or sell any security. Investment decisions and their risks rest solely with the reader.
Track ResMed share price daily: live levels, support/resistance and our full ResMed analysis history.
Take the quizWhat Kind of Holiday Spender Are You? Take the Black Friday QuizStart →
Lifestyle7 Signs Your Social Battery Is Running Low (and Why You Keep Cancelling Plans)
Lifestyle · Food & HealthThanksgiving Food Safety: How Long Leftovers Last and the Safe Turkey Temperature
Lifestyle7 Quiet Habits of Emotionally Intelligent People, According to Psychologists
LifestylePeople Who Don’t Like Celebrating Their Birthday Often Share These 7 Traits




















